GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction
Retrieved on:
Tuesday, May 30, 2023
LLP, Common stock, Note, Tripura Merger Agreement, PBC, Fall line, Committee, Disclosure, Special, Dollar for Dollar, GRNA, Acquisition, Private company limited by shares, Myers, Privately held company, Report of the Special Committee on the Termination of the National Emergency, Highlander: The Series (season 2), Roth Capital Partners, Reverse convertible securities, Common, Cryptocurrency, Security (finance)
LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction valuing the Company at approximately $45.5 million.
Key Points:
- LEXINGTON, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced that the Company has entered into a definitive agreement (the “Merger Agreement”) to be acquired by a group of buyers led by Fall Line Capital, LLC (“Fall Line”) in an all-cash transaction valuing the Company at approximately $45.5 million.
- Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023.
- Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement.
- O’Melveny & Myers LLP is serving as legal counsel to Fall Line.